세계의 당뇨병 전증 시장 조사 보고서 : 산업 분석, 규모, 점유율, 성장, 동향 및 예측(2025-2033년)

Global Prediabetes Market size is anticipated to grow from USD 240.76 Million in 2024 to USD 470.55 Million by 2033, showcasing a robust Compound Annual Growth Rate (CAGR) of 7.73% during the forecast period of 2026 to 2033.

The global prediabetes market is poised for significant growth, driven by the increasing prevalence of prediabetes and the rising awareness of its health implications. Prediabetes, characterized by elevated blood sugar levels that are not yet high enough to be classified as diabetes, affects millions of individuals worldwide. As healthcare providers and patients recognize the importance of early intervention to prevent the progression to type 2 diabetes, the demand for screening, diagnostic tools, and management solutions for prediabetes is expected to rise substantially, fostering innovation and investment in this critical market.

Moreover, advancements in digital health technologies and personalized medicine are anticipated to further boost the prediabetes market. The development of mobile health applications, wearable devices, and telehealth platforms enables individuals to monitor their blood sugar levels, track lifestyle changes, and receive personalized guidance from healthcare professionals. Additionally, the growing emphasis on lifestyle modification programs, including dietary changes and physical activity, is driving the demand for comprehensive management solutions that empower individuals to take control of their health. As the healthcare landscape continues to evolve, the market for prediabetes solutions is likely to witness a surge in demand for innovative products and services that cater to diverse patient needs.

In addition, the increasing focus on regulatory compliance and public health initiatives is expected to shape the future of the prediabetes market. As governments and health organizations implement programs aimed at raising awareness and promoting preventive measures, the demand for prediabetes screening and management solutions will continue to rise. Collaborative efforts between healthcare providers, technology developers, and regulatory bodies will be essential in driving these advancements, ensuring that the prediabetes market remains responsive to the evolving needs of patients and healthcare systems.

Our reports are meticulously crafted to provide clients with comprehensive and actionable insights into various industries and markets. Each report encompasses several critical components to ensure a thorough understanding of the market landscape:

Market Overview: A detailed introduction to the market, including definitions, classifications, and an overview of the industry's current state.

Market Dynamics: In-depth analysis of key drivers, restraints, opportunities, and challenges influencing market growth. This section examines factors such as technological advancements, regulatory changes, and emerging trends.

Segmentation Analysis: Breakdown of the market into distinct segments based on criteria like product type, application, end-user, and geography. This analysis highlights the performance and potential of each segment.

Competitive Landscape: Comprehensive assessment of major market players, including their market share, product portfolio, strategic initiatives, and financial performance. This section provides insights into the competitive dynamics and key strategies adopted by leading companies.

Market Forecast: Projections of market size and growth trends over a specified period, based on historical data and current market conditions. This includes quantitative analyses and graphical representations to illustrate future market trajectories.

Regional Analysis: Evaluation of market performance across different geographical regions, identifying key markets and regional trends. This helps in understanding regional market dynamics and opportunities.

Emerging Trends and Opportunities: Identification of current and emerging market trends, technological innovations, and potential areas for investment. This section offers insights into future market developments and growth prospects.

SEGMENTATION COVERED IN THE REPORT

By Drug Class

• Diguanide
• Thiazolidinediones
• Glucagon-Like Peptide-1 Agonists (GLP-1)
• SGLT2 Inhibitors
• DPP-4 Inhibitors
• Others

By Age Group

• Children (12-18 Years)
• Adults (18-49)
• Elderly (50+)
• COMPANIES PROFILED
• Novo Nordisk
• Valbiotis
• RESVERLOGIX
• Caelus Health
• SciMar
• Boston Therapeutics
• Aphaia Pharma
• AstraZeneca
• Bristol-Myers Squibb
• The above list can be customized.

TABLE OF CONTENTS

1 . PREFACE

• 1.1. Report Description
  • 1.1.1. Objective
  • 1.1.2. Target Audience
  • 1.1.3. Unique Selling Proposition (USP) offerings
• 1.2. Research Scope
• 1.3. Research Methodology
  • 1.3.1. Market Research Process
  • 1.3.2. Market Research Methodology

2 . EXECUTIVE SUMMARY

• 2.1. Highlights of Market
• 2.2. Global Market Snapshot

3 . PREDIABETES INDUSTRY ANALYSIS

• 3.1. Introduction - Market Dynamics
• 3.2. Market Drivers
• 3.3. Market Restraints
• 3.4. Opportunities
• 3.5. Industry Trends
• 3.6. Porter's Five Force Analysis
• 3.7. Market Attractiveness Analysis
  • 3.7.1 Market Attractiveness Analysis By Drug Class
  • 3.7.2 Market Attractiveness Analysis By Age Group
  • 3.7.3 Market Attractiveness Analysis By Region

4 . VALUE CHAIN ANALYSIS

• 4.1. Value Chain Analysis
• 4.2. Raw Material Analysis
  • 4.2.1. List of Raw Materials
  • 4.2.2. Raw Material Manufactures List
  • 4.2.3. Price Trend of Key Raw Materials
• 4.3. List of Potential Buyers
• 4.4. Marketing Channel
  • 4.4.1. Direct Marketing
  • 4.4.2. Indirect Marketing
  • 4.4.3. Marketing Channel Development Trend

5 . GLOBAL PREDIABETES MARKET ANALYSIS BY DRUG CLASS

• 5.1 Overview by Drug Class
• 5.2 Historical and Forecast Data
• 5.3 Analysis by Drug Class
• 5.4 Diguanide Historic and Forecast Sales by Regions
• 5.5 Thiazolidinediones Historic and Forecast Sales by Regions
• 5.6 Glucagon-Like Peptide-1 Agonists (GLP-1) Historic and Forecast Sales by Regions
• 5.7 SGLT2 Inhibitors Historic and Forecast Sales by Regions
• 5.8 DPP-4 Inhibitors Historic and Forecast Sales by Regions
• 5.9 Others Historic and Forecast Sales by Regions

6 . GLOBAL PREDIABETES MARKET ANALYSIS BY AGE GROUP

• 6.1 Overview by Age Group
• 6.2 Historical and Forecast Data
• 6.3 Analysis by Age Group
• 6.4 Children (12-18 Years) Historic and Forecast Sales by Regions
• 6.5 Adults (18-49) Historic and Forecast Sales by Regions
• 6.6 Elderly (50+) Historic and Forecast Sales by Regions

7 . GLOBAL PREDIABETES MARKET ANALYSIS BY GEOGRAPHY

• 7.1. Regional Outlook
• 7.2. Introduction
• 7.3. North America Sales Analysis
  • 7.3.1. Overview, Historic and Forecast DataSales Analysis
  • 7.3.2. North America By Segment Sales Analysis
  • 7.3.3. North America By Country Sales Analysis
  • 7.3.4. United State Sales Analysis
  • 7.3.5. Canada Sales Analysis
  • 7.3.6. Mexico Sales Analysis
• 7.4. Europe Sales Analysis
  • 7.4.1. Overview, Historic and Forecast DataSales Analysis
  • 7.4.2. Europe by Segment Sales Analysis
  • 7.4.3. Europe by Country Sales Analysis
  • 7.4.4. United Kingdom Sales Analysis
  • 7.4.5. France Sales Analysis
  • 7.4.6. Germany Sales Analysis
  • 7.4.7. Italy Sales Analysis
  • 7.4.8. Russia Sales Analysis
  • 7.4.9. Rest Of Europe Sales Analysis
• 7.5. Asia Pacific Sales Analysis
  • 7.5.1. Overview, Historic and Forecast DataSales Analysis
  • 7.5.2. Asia Pacific by Segment Sales Analysis
  • 7.5.3. Asia Pacific by Country Sales Analysis
  • 7.5.4. China Sales Analysis
  • 7.5.5. India Sales Analysis
  • 7.5.6. Japan Sales Analysis
  • 7.5.7. South Korea Sales Analysis
  • 7.5.8. Australia Sales Analysis
  • 7.5.9. South East Asia Sales Analysis
  • 7.5.10. Rest Of Asia Pacific Sales Analysis
• 7.6. Latin America Sales Analysis
  • 7.6.1. Overview, Historic and Forecast DataSales Analysis
  • 7.6.2. Latin America by Segment Sales Analysis
  • 7.6.3. Latin America by Country Sales Analysis
  • 7.6.4. Brazil Sales Analysis
  • 7.6.5. Argentina Sales Analysis
  • 7.6.6. Peru Sales Analysis
  • 7.6.7. Chile Sales Analysis
  • 7.6.8. Rest of Latin America Sales Analysis
• 7.7. Middle East Africa Sales Analysis
  • 7.7.1. Overview, Historic and Forecast DataSales Analysis
  • 7.7.2. Middle East Africa by Segment Sales Analysis
  • 7.7.3. Middle East Africa by Country Sales Analysis
  • 7.7.4. Saudi Arabia Sales Analysis
  • 7.7.5. UAE Sales Analysis
  • 7.7.6. Israel Sales Analysis
  • 7.7.7. South Africa Sales Analysis
  • 7.7.8. Rest Of Middle East And Africa Sales Analysis

8 . COMPETITIVE LANDSCAPE OF THE PREDIABETES COMPANIES

• 8.1. Prediabetes Market Competition
• 8.2. Partnership/Collaboration/Agreement
• 8.3. Merger And Acquisitions
• 8.4. New Product Launch
• 8.5. Other Developments

9 . COMPANY PROFILES OF PREDIABETES INDUSTRY

• 9.1. Top Companies Market Share Analysis
• 9.2. Market Concentration Rate
• 9.3. Novo Nordisk
  • 9.3.1. Company Overview
  • 9.3.2. Company Revenue
  • 9.3.3. Products
  • 9.3.4. Recent Developments
• 9.4. Valbiotis
  • 9.4.1. Company Overview
  • 9.4.2. Company Revenue
  • 9.4.3. Products
  • 9.4.4. Recent Developments
• 9.5. Resverlogix
  • 9.5.1. Company Overview
  • 9.5.2. Company Revenue
  • 9.5.3. Products
  • 9.5.4. Recent Developments
• 9.6. Caelus Health
  • 9.6.1. Company Overview
  • 9.6.2. Company Revenue
  • 9.6.3. Products
  • 9.6.4. Recent Developments
• 9.7. SciMar
  • 9.7.1. Company Overview
  • 9.7.2. Company Revenue
  • 9.7.3. Products
  • 9.7.4. Recent Developments
• 9.8. Boston Therapeutics
  • 9.8.1. Company Overview
  • 9.8.2. Company Revenue
  • 9.8.3. Products
  • 9.8.4. Recent Developments
• 9.9. Aphaia Pharma
  • 9.9.1. Company Overview
  • 9.9.2. Company Revenue
  • 9.9.3. Products
  • 9.9.4. Recent Developments
• 9.10. AstraZeneca
  • 9.10.1. Company Overview
  • 9.10.2. Company Revenue
  • 9.10.3. Products
  • 9.10.4. Recent Developments
• 9.11. Bristol-Myers Squibb
  • 9.11.1. Company Overview
  • 9.11.2. Company Revenue
  • 9.11.3. Products
  • 9.11.4. Recent Developments

Note - in company profiling, financial details and recent development are subject to availability or might not be covered in case of private companies